A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension

Inclusion Criteria: * Males or Females * Aged from 18 to 70 years * Had a history of essential hypertension * Average sitting diastolic blood pressure≧90mmHg，but≦109mmHg Exclusion Criteria: * Malignant hypertension * Average sitting systolic blood pressure≧180mmHg * Type 2 diabetes with hemoglobin A1c≥9% * Type 1 diabetes * New York Heart Association class Ⅱ-Ⅳ congestive heart-failure * Unstable angina * Second or third degree heart block or history of sick sinus syndrome unless a pacemaker was in place * Atrial fibrillation * Bradycardia (\<60 bpm, seated) * Asthma or other obstructive pulmonary disease * History of myocardial infarction * Stroke in the 6 months before screening * Known contraindications to β-adrenergic blocker therapy * Glutamic-oxaloacetic transaminase and/or glutamic-pyruvic transaminase\>3 times upper limit of normal * Crea\>2 times upper limit of normal * Pregnancy or lactation